TWST - Twist Bioscience Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.74
-0.26 (-1.13%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close23.00
Open22.80
Bid21.50 x 1400
Ask24.35 x 1300
Day's Range22.65 - 23.90
52 Week Range19.64 - 35.95
Volume195,268
Avg. Volume303,170
Market Cap756.351M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.92
Earnings DateDec 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.67
  • Business Wire

    Twist Bioscience Selected as DNA Synthesis Provider for DNA Data Storage Project Under Intelligence Advanced Research Projects Activity (IARPA) Molecular Information Storage (MIST) Program

    Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has been selected as a subcontractor to Georgia Tech Research Institute (GTRI) to undertake the DNA synthesis portion of the Molecular Information Storage (MIST) program through a contract with the Intelligence Advanced Research Projects Activity (IARPA). DNA has the ability to store large amounts of data over long periods of time in a very dense format, however today this storage technology is not cost efficient, nor widely available. The aim of the project, termed Scalable Molecular Archival Software & Hardware (SMASH), is to make long-term DNA data storage accessible and commercially viable within the next three to five years.

  • Business Wire

    Twist Bioscience Announces Strategic Collaboration With Schrödinger for Drug Discovery

    Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today a collaboration with Schrödinger, Inc., a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.

  • Business Wire

    Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer Setting Stage for Future Growth

    Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick Weiss to chief operating officer and the appointment of Bill Banyai, Ph.D., as senior vice president of advanced development and general manager of data storage. Both executive appointments support Twist’s drive for commercial growth.

  • Business Wire

    Twist Bioscience to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. Pacific Time in San Francisco.

  • Hedge Funds Have Never Been This Bullish On Twist Bioscience Corporation (TWST)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Twist Bioscience Corporation (TWST)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Benzinga

    The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • Business Wire

    Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results

    Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2019 ended September 30, 2019.

  • Business Wire

    Twist Bioscience and Pandion Therapeutics Expand Antibody Optimization Collaboration

    Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an expanded antibody optimization collaboration with Pandion Therapeutics. Based on the successful completion of its first project for Pandion, Twist Biopharma, a division of Twist Bioscience, will apply its antibody optimization platform to additional Pandion antibodies. Pandion is developing modular biologics and antibodies for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases.

  • If You Had Bought Twist Bioscience (NASDAQ:TWST) Stock A Year Ago, You'd Be Sitting On A 13% Loss, Today
    Simply Wall St.

    If You Had Bought Twist Bioscience (NASDAQ:TWST) Stock A Year Ago, You'd Be Sitting On A 13% Loss, Today

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • Business Wire

    Twist Bioscience to Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on Wednesday, December 11, 2019

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2019, following the close of market on Wednesday, December 11, 2019. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com.

  • Business Wire

    Twist Bioscience Promotes Patrick J. Finn, Ph.D., to Chief Commercial Officer

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick J. Finn, Ph.D., to the newly-created position of chief commercial officer. “Paddy built our global sales, marketing and support organizations from the ground up, led the launch of both our commercial synthetic biology and genomics offerings, and continues to drive top line growth and market penetration for all business segments,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

  • Business Wire

    Twist Bioscience to Present at Upcoming Investor Conferences

    Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced

  • Business Wire

    Twist Biopharma Implements Genedata Biologics to Advance Synthetic Biology-driven Antibody Discovery

    First-in-class software platform digitalizes Twist Biopharma’s innovative antibody lead identification and optimization

  • Business Wire

    Twist Bioscience to Provide Target Enrichment Products for MGI in Europe and Asia Pacific

    -- Companies Combine Best-in-Class Product Lines for Next-Generation Sequencing --

  • Business Wire

    Twist Bioscience Appoints Seasoned Life Sciences Industry Executive Nicolas M. Barthelemy to Board of Directors

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Nicolas M. Barthelemy to its board of directors. Mr. Barthelemy brings extensive experience, both as an operational executive and board member, in the areas of biopharmaceutical, life science tools and molecular diagnostics. “Nicolas brings incredibly relevant global commercial operations and manufacturing expertise that will be invaluable as we continue to innovate to provide exceptional products for our customers,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

  • Business Wire

    Praesens Foundation, Institut Pasteur, Institut Pasteur de Dakar, University of Nebraska Medical Center, Twist Bioscience Consortium Win Prix Galien MedStartUp Award

    The Praesens Foundation, the Institut Pasteur, the Institut Pasteur de Dakar, University of Nebraska Medical Center and Twist Bioscience Corporation (TWST) today announced that the consortium is the winner of the Prix Galien MedStartUp award in the category: 'Best Collaboration Dedicated to the Developing or Underserved Populations Worldwide'. The consortium works together to develop, quantify and scale up a range of innovative solutions on the continent of Africa to ensure better preparedness and response to infectious disease outbreaks. “Past and recent disease outbreaks of Ebola, SARS, MERS-CoV, Zika and Dengue, have shown that infectious diseases continue to affect many lives while also representing social, economic, and national security threats that can quickly evolve into global health crises1, causing major human suffering and imposing enormous economic damage,” said Dr. Rudi Pauwels, Founder and President of Praesens Foundation.

  • Business Wire

    Twist Bioscience Showcases Next-Generation Sequencing Products and Results at American Society for Human Genetics 2019 Annual Meeting

    Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of new customer, company and collaborator data using the Twist Bioscience target enrichment and library preparation products for next-generation sequencing (NGS). In addition, Twist Bioscience will showcase the results of adding formalin-fixed paraffin-embedded (FFPE) and saliva sample preparation workflows with its NGS products, resulting in uniform sequence coverage of the target area of interest within the genome. In a company-sponsored workshop today, D. Gigi Ostrow, Ph.D., translational genomics manager for Children’s Hospital of Los Angeles will present “Our Twist on Cancer Predisposition Testing”, Duane C. Hassane, Ph.D., assistant professor of computational biomedicine in medicine at Weill Cornell Medical College, will present “From Pre-AML to Pre-CISE-1: Clonal Hematopoiesis, Acute Myeloid Leukemia and Molecular Aging”, and David Kupec of Twist Bioscience will provide an NGS tools product overview.

  • Business Wire

    Twist Bioscience Showcases New Innovation Lab at SynBioBeta 2019

    -- Previews Disruptive Gene Pools Product that Includes up to 180,000 Genes for Drug Discovery, Protein Screening and More, at $0.04 per Base Pair –

  • GuruFocus.com

    Twist Bioscience Corp (TWST) COO William Banyai Sold $614,240 of Shares

    COO of Twist Bioscience Corp (30-Year Financial, Insider Trades) William Banyai (insider trades) sold 22,000 shares of TWST on 08/27/2019 at an average price of $27.92 a share. Continue reading...

  • Twist Bioscience Grows Q3 Revenue 108%, but Losses Pile Up
    Motley Fool

    Twist Bioscience Grows Q3 Revenue 108%, but Losses Pile Up

    The business reported an operating loss of $77 million in the first nine months of fiscal 2019.

  • Twist Bioscience Corporation (TWST) Q2 2019 Earnings Call Transcript
    Motley Fool

    Twist Bioscience Corporation (TWST) Q2 2019 Earnings Call Transcript

    TWST earnings call for the period ending June 30, 2019.